Table 2.
Genetic composition, epitope, and neutralization function of H7.HK mAbs
| mAb ID | Origin | Time point | Isotype | V-gene (SHM%) | CDR3 length in amino acid | Epitope | Neutralization |
|---|---|---|---|---|---|---|---|
| H7.HK1 | Human | 1 year post recovery | IgG1 |
HV4-59 (8%) KV2-28 (6%) |
H3: 11, L3: 9 | H7 HA1 | Yes |
| H7.HK2 | Human | 1 year post recovery | IgG1 |
HV4-59 (10%) KV2-28 (6%) |
H3: 11, L3: 9 | H7 HA1 | Yes |
| H7.HK3 | Human | 1 year post recovery | IgG1 |
HV7-4-1 (5%) KV1-5 (7%) |
H3: 14, L3: 8 | H7 HA1 | No |
| H7.HK4 | Human | 1 year post recovery | IgG1 |
HV4-61 (7%) KV1-16 (5%) |
H3: 13, L3: 9 | H7 HA2 | No |